MDBR Pilot Grant Program

Orphan Disease Center Million Dollar Bike Ride Pilot Grant Program

by | Aug 23, 2019 | 0 comments

Calling all Charcot-Marie-Tooth Researchers!

team cmt bikeThe ODC MDBR Pilot Grant Program provides a one‐year grant to support research related to a rare disease represented in the 2019 Million Dollar Bike Ride. HNF reached its $30,165 goal which was generously matched by the Orphan Disease Center. We want to thank all our riders and donors for participating. The grant will be a 1 year award with an optional 6 month no cost extension for a one time award of $60,330 starting January 1, 2020.




All individuals holding a faculty‐level appointment at an academic institution or a senior scientific position at a non-profit institution or foundation are eligible to respond to this RFA.

Letter of Interest Instructions:

Please visit the ODC website (link below) to submit your Letter of Interest (LOI). This one-page LOI is due no later than Monday, September 23, 2019 by 8pm (EST).

Click RFA guidelines and scroll down to #7 for details for CMT grant.

Full Application Instructions and Review Procedure

NOTE: Full Application is by invitation only after review of Pre-Application 

Proposal Due Date: Thursday, October 24, 2019 no later than 8pm (EST). Full application documents are to be uploaded on our website, by invitation only.

Learn more on this topic

Related Blog Posts

Pharnext Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) Designation by UK Medicines and Healthcare Products Regulatory Agency

United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to its lead drug candidate, PXT3003, for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A) in patients 16 years and older.

Pharnext raises € 7.7 million in a private placement

Pharnext SA (FR0011191287 – ALPHA) (the “Company”), a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on its PLEOTHERAPY artificial intelligence platform harnessing big genomics data and network pharmacology, today announced a capital raise of circa € 7.7 million by way of issuance of 1,799,061 new ordinary shares (the “New Shares”) with one warrant attached each (together with the New Shares, the “ABSA”).

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news